Ting-Yuan David Cheng1,2, Amy K Darke3, Mary W Redman3, Gary R Zirpoli4, Warren Davis1, Rochelle Payne Ondracek1, Wiam Bshara5, Angela R Omilian5, Robert Kratzke6, Mary E Reid1, Julian R Molina7, Jill M Kolesar8, Yuhchyau Chen9, Robert M MacRae10, James Moon3, Philip Mack11, David R Gandara11, Karen Kelly11, Regina M Santella12, Kathy S Albain13, Christine B Ambrosone1. 1. Department of Cancer Prevention and Control and Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY. 2. Department of Epidemiology, University of Florida, Gainesville, FL. 3. SWOG Statistical Center/Fred Hutchinson Cancer Research Center, Seattle, WA. 4. Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 5. Department of Pathology, Roswell Park Cancer Institute, Buffalo, NY. 6. Department of Medicine, University of Minnesota, Minneapolis, MN. 7. Department of Oncology, Mayo Clinic, Rochester, MN. 8. School of Pharmacy, University of Wisconsin-Madison, Madison, WI. 9. Department of Radiation Oncology, University of Rochester Medical Center, Rochester, NY. 10. The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada. 11. Department of Internal Medicine, UC Davis Comprehensive Cancer Center, Sacramento, CA. 12. Department of Environmental Health Sciences, Columbia University, New York, NY. 13. Loyola University Chicago Stritch School of Medicine, Maywood, IL.
Abstract
Background: To what extent steroid hormones contribute to lung cancer in male and female never smokers and smokers is unclear. We examined expression of hormone receptors in lung tumors by sex and smoking. Methods: Patients with primary non-small cell lung cancer were recruited into an Intergroup study in the United States and Canada, led by SWOG (S0424). Tumors from 813 cases (450 women and 363 men) were assayed using immunohistochemistry for estrogen receptor (ER)-α, ER-β, progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Linear regression was used to examine differences in expression by sex and smoking status. Cox proportional hazard models were used to estimate survival associated with the receptors. All statistical tests were two-sided. Results: In ever smokers, postmenopause and oral contraceptive use were associated with lower nuclear ER-β (P = .02) and total (nuclear + cytoplasmic) PR expression (P = .02), respectively. Women had lower cytoplasmic ER-α (regression coefficient [β], or differences in H-scores = -15.8, P = .003) and nuclear ER-β (β = -12.8, P = .04) expression than men, adjusting for age, race, and smoking. Ever smokers had both higher cytoplasmic ER-α (β = 45.0, P < .001) and ER-β (β = 25.9, P < .001) but lower total PR (β = -42.1, P < .001) than never smokers. Higher cytoplasmic ER-α and ER-β were associated with worse survival (hazard ratio = 1.73, 95% confidence interval [CI] = 1.15 to 2.58, and HR = 1.59, 95% CI = 1.08 to 2.33, respectively; quartiles 4 vs 1). Conclusions: Lower expression of nuclear ER-β in women supports the estrogen hypothesis in lung cancer etiology. Increasing cytoplasmic ER-α and ER-β and decreasing PR protein expression may be mechanisms whereby smoking disrupts hormone pathways.
Background: To what extent steroid hormones contribute to lung cancer in male and female never smokers and smokers is unclear. We examined expression of hormone receptors in lung tumors by sex and smoking. Methods:Patients with primary non-small cell lung cancer were recruited into an Intergroup study in the United States and Canada, led by SWOG (S0424). Tumors from 813 cases (450 women and 363 men) were assayed using immunohistochemistry for estrogen receptor (ER)-α, ER-β, progesterone receptor (PR), and humanepidermal growth factor receptor 2 (HER2). Linear regression was used to examine differences in expression by sex and smoking status. Cox proportional hazard models were used to estimate survival associated with the receptors. All statistical tests were two-sided. Results: In ever smokers, postmenopause and oral contraceptive use were associated with lower nuclear ER-β (P = .02) and total (nuclear + cytoplasmic) PR expression (P = .02), respectively. Women had lower cytoplasmic ER-α (regression coefficient [β], or differences in H-scores = -15.8, P = .003) and nuclear ER-β (β = -12.8, P = .04) expression than men, adjusting for age, race, and smoking. Ever smokers had both higher cytoplasmic ER-α (β = 45.0, P < .001) and ER-β (β = 25.9, P < .001) but lower total PR (β = -42.1, P < .001) than never smokers. Higher cytoplasmic ER-α and ER-β were associated with worse survival (hazard ratio = 1.73, 95% confidence interval [CI] = 1.15 to 2.58, and HR = 1.59, 95% CI = 1.08 to 2.33, respectively; quartiles 4 vs 1). Conclusions: Lower expression of nuclear ER-β in women supports the estrogen hypothesis in lung cancer etiology. Increasing cytoplasmic ER-α and ER-β and decreasing PR protein expression may be mechanisms whereby smoking disrupts hormone pathways.
Authors: Ann G Schwartz; Roberta M Ray; Michele L Cote; Judith Abrams; Robert J Sokol; Susan L Hendrix; Chu Chen; Rowan T Chlebowski; F Allan Hubbell; Charles Kooperberg; JoAnn E Manson; Mary Jo O'Sullivan; Thomas Rohan; Marcia L Stefanick; Jean Wactawski-Wende; Heather Wakelee; Michael S Simon Journal: J Thorac Oncol Date: 2015-07 Impact factor: 15.609
Authors: Christine Bouchardy; Simone Benhamou; Robin Schaffar; Helena M Verkooijen; Gerald Fioretta; Hyma Schubert; Vincent Vinh-Hung; Jean-Charles Soria; Georges Vlastos; Elisabetta Rapiti Journal: Cancer Date: 2011-01-24 Impact factor: 6.860
Authors: Ann G Schwartz; Geoffrey M Prysak; Valerie Murphy; Fulvio Lonardo; Harvey Pass; Jan Schwartz; Sam Brooks Journal: Clin Cancer Res Date: 2005-10-15 Impact factor: 12.531
Authors: Rowan T Chlebowski; Garnet L Anderson; JoAnn E Manson; Ann G Schwartz; Heather Wakelee; Margery Gass; Rebecca J Rodabough; Karen C Johnson; Jean Wactawski-Wende; Jane Morley Kotchen; Judith K Ockene; Mary Jo O'Sullivan; F Allan Hubbell; Jason W Chien; Chu Chen; Marcia L Stefanick Journal: J Natl Cancer Inst Date: 2010-08-13 Impact factor: 13.506
Authors: Heather A Wakelee; Ellen T Chang; Scarlett L Gomez; Theresa H Keegan; Diane Feskanich; Christina A Clarke; Lars Holmberg; Lee C Yong; Laurence N Kolonel; Michael K Gould; Dee W West Journal: J Clin Oncol Date: 2007-02-10 Impact factor: 44.544
Authors: Mei Jiang; Aline F Fares; Daniel Shepshelovich; Ping Yang; David Christiani; Jie Zhang; Kouya Shiraishi; Brid M Ryan; Chu Chen; Ann G Schwartz; Adonina Tardon; Sanjay Shete; Matthew B Schabath; M Dawn Teare; Loic Le Marchand; Zuo-Feng Zhang; John K Field; Hermann Brenner; Nancy Diao; Juntao Xie; Takashi Kohno; Curtis C Harris; Angela S Wenzlaff; Guillermo Fernandez-Tardon; Yuanqing Ye; Fiona Taylor; Lynne R Wilkens; Michael Davies; Yi Liu; Matt J Barnett; Gary E Goodman; Hal Morgenstern; Bernd Holleczek; Sera Thomas; M Catherine Brown; Rayjean J Hung; Wei Xu; Geoffrey Liu Journal: Lung Cancer Date: 2020-12-04 Impact factor: 5.705
Authors: Hang Li; Jun Che; Mian Jiang; Ming Cui; Guoxing Feng; Jiali Dong; Shuqin Zhang; Lu Lu; Weili Liu; Saijun Fan Journal: Cell Commun Signal Date: 2020-09-17 Impact factor: 5.712
Authors: Ivan S Grebenshchikov; Valentin A Ustinov; Artem E Studennikov; Vadim I Ivanov; Natalia V Ivanova; Victor A Titov; Natalja E Vergbickaya Journal: Oncotarget Date: 2019-08-20